LENZ director granted 22,100 stock options

LENZ Therapeutics director James W. McCollum received a new stock option grant for 22,100 shares of common stock.

Rhea-AI Filing Summary

LENZ Therapeutics director James W. McCollum received a new stock option grant for 22,100 shares of common stock. The option has an exercise price of $6.63 per share and expires on June 15, 2036. Following this grant, he holds options for 22,100 shares directly.

According to the terms, all 22,100 option shares vest in a single tranche if he continues serving as an Outside Director through the vesting date. Vesting occurs on the earlier of June 15, 2027 or the date of the next annual meeting of stockholders.

Insider Trade Summary

Grant/Award: 22,100 shares

Grant/Award 1 txn

Insider MCCOLLUM JAMES W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	22,100	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 22,100 contracts (Direct)

Footnotes (1)

1. F1. Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders.

Key Figures

Option shares granted: 22,100 shares Exercise price: $6.63 per share Expiration date: June 15, 2036 +3 more

6 metrics

Option shares granted 22,100 shares Stock Option (right to buy) grant on June 15, 2026

Exercise price $6.63 per share Conversion or exercise price of granted options

Expiration date June 15, 2036 Option term end for this grant

Shares underlying options 22,100 shares Underlying common stock tied to this option award

Derivative holdings after grant 22,100 options Total shares following transaction, direct ownership

Vesting date trigger June 15, 2027 Or earlier on date of next annual meeting, subject to service

Key Terms

Stock Option (right to buy, Outside Director, annual meeting of stockholders, Common Stock

4 terms

Stock Option (right to buy financial

"security_title: "Stock Option (right to buy)""

Outside Director financial

"Subject to the Reporting Person continuing to be an Outside Director"

annual meeting of stockholders financial

"the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders"

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LENZ director James W. McCollum report on this Form 4 for LENZ?

James W. McCollum reported a grant of stock options for 22,100 shares of LENZ Therapeutics common stock. These options are a compensation-related award, not an open-market purchase or sale, and were reported as a derivative acquisition transaction.

What is the exercise price and expiration date of McCollum’s LENZ stock options?

The granted stock options have an exercise price of $6.63 per share and an expiration date of June 15, 2036. This means he can buy up to 22,100 LENZ shares at $6.63 any time before that expiration, once the options vest.

How many LENZ shares are covered by the new stock option grant to James W. McCollum?

The new stock option grant covers 22,100 shares of LENZ Therapeutics common stock. After this award, McCollum’s total reported derivative holdings from this grant are 22,100 option shares, all held in a direct ownership capacity according to the filing.

When do James W. McCollum’s LENZ stock options vest under this award?

All 22,100 option shares vest in a single tranche if he remains an Outside Director. Vesting occurs on the earlier of June 15, 2027, or the date of the next annual meeting of stockholders, subject to his continued service through that date.

Is this LENZ Form 4 transaction a market purchase or sale of common stock?

No, the Form 4 reports a grant of stock options, not a market trade in common shares. The transaction code is “A” for a grant or award acquisition, reflecting a compensation-related derivative award rather than an open-market buy or sell.

What is James W. McCollum’s reported LENZ derivative position after this transaction?

After this transaction, McCollum is reported as holding 22,100 stock options linked to LENZ common stock. All of these options are tied to the new grant, with direct ownership reported and no additional remaining derivative positions listed in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 08:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCCOLLUM JAMES W

(Last) (First) (Middle)

C/O LENZ THERAPEUTICS, INC.

201 LOMAS SANTA FE DRIVE, SUITE 300

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LENZ Therapeutics, Inc. [ LENZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.63	06/15/2026		A		22,100		(1)	06/15/2036	Common Stock	22,100	$0	22,100	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders.

Remarks:

	/s/ Daniel R. Chevallard, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)